References of "Neven, P"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSafety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm, Expanded-Access Multicenter Trial (BALLET).
Jerusalem, Guy ULg; Mariani, G.; Ciruelos, E. M. et al

in Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (2016)

BACKGROUND: This European phase 3b, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a patient population similar to BOLERO-2. PATIENTS AND METHODS: Postmenopausal women aged (3 ... [more ▼]

BACKGROUND: This European phase 3b, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a patient population similar to BOLERO-2. PATIENTS AND METHODS: Postmenopausal women aged (3)18 years with hormone receptor-positive, human epidermal growth factor-receptor-2-negative advanced breast cancer (ABC) recurring/progressing during/after prior non-steroidal aromatase inhibitors (NSAIs) were enrolled. Primary objective was safety of EVE plus EXE based on frequency of adverse events (AEs), and serious AEs (SAEs). Secondary objective was to evaluate AEs of grade 3/4 severity. RESULTS: Median treatment duration was 5.1 months (95% CI, 4.8-5.6) for EVE and 5.3 months (95% CI, 4.8-5.6) for EXE. Overall, 2131 patients were included in the analysis; 81.8% of patients experienced EVE- or EXE-related or EVE/EXE-related AEs (investigator assessed); 27.2% were of grade 3/4 severity. The most frequently reported non-hematologic AEs were (overall %, % EVE-related) stomatitis (52.8%; 50.8%) and asthenia (22.8%; 14.6%). The most frequently reported hematologic AE were (overall %, % EVE-related) anemia (14.4%; 8.1%) and thrombocytopenia (5.9%; 4.6%). AE-related treatment discontinuations were higher in elderly ((3)70 years) versus non-elderly patients (23.8% vs. 13.0%). The incidence of EVE-related AEs in both elderly and non-elderly patients appeared to be lower in first-line ABC versus later lines. The incidence of AEs (including stomatitis/pneumonitis) was independent of BMI status (post-hoc analysis). Overall, 8.5% of patients experienced at least one EVE-related SAE. Of the 121 on-treatment deaths (5.7%), 66 (3.1%) deaths were due to disease progression and 46 (2.2%) due to AEs; 4 deaths were suspected to be EVE-related. CONCLUSIONS: This is the largest ever reported safety dataset on a general patient population presenting ABC treated with EVE plus EXE and included a sizeable elderly subset. Although the patients were more heavily pretreated, the safety profile of EVE plus EXE in BALLET was consistent with BOLERO-2. CLINICAL TRIAL REGISTRATION: EudraCT Number: 2012-000073-23. [less ▲]

Detailed reference viewed: 59 (5 ULg)
Full Text
Peer Reviewed
See detailThe 2006 adjuvant Trastuzumab convention in Belgium: 5 years later
Vanderhaegen, J; Paridaens, R; Piccart, M et al

Poster (2013, March)

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailThe 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later
VANDERHAEGEN, J; PARIDAENS, R; PICCART, M et al

in Cancer Research (2012)

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailTrastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen, I.; Canon, J. L.; Cocquyt, V. et al

in Acta Clinica Belgica (2009), 64(2), 100-12

Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium for the treatment of metastatic HER2+ breast ... [more ▼]

Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium for the treatment of metastatic HER2+ breast cancer and since June 2007 also in adjuvant therapy of HER2+ early stage breast cancer. The purpose of this study was to estimate the cost-effectiveness from the Belgian health care payer perspective of reimbursing trastuzumab in the Latter indication. A Markov state transition model was designed to adequately capture the natural history and course of disease for early stage breast cancer patients, and to simulate cost and disease progression over a life time perspective. The model estimates differences in outcomes for patients treated with adjuvant trastuzumab during 1 year compared to current therapy, and captures cost consequences and health benefits of trastuzumab treatment. Health benefits were expressed in terms of quality-adjusted life years gained, and future benefits were discounted at 1.5%. Costs were calculated from the perspective of the Belgian authorities' health care budget, and future costs were discounted at 3%. Where relevant, the costs per Markov state were obtained from the IMS Hospital Disease database. Additionally, an expert opinion analysis on resource use during the follow-up of treated early breast cancer patients provided the cost estimates for states with minor or without hospital costs. The incremental cost-effectiveness ratio based on a life time simulation was estimated at Euro 10,315 per quality-adjusted life year gained. It can be concluded that trastuzumab treatment of HER2+ early stage breast cancer patients is cost-effective from the perspective of the Belgian health care authorities. [less ▲]

Detailed reference viewed: 38 (2 ULg)
Peer Reviewed
See detailConception et synthèse d’outils pharmacologiques originaux pour l’étude des récepteurs au thromboxane
Moray, A. L.; Dogne, J. M.; Neven, P. et al

Poster (2007, May)

Detailed reference viewed: 17 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of TP receptor antagonists by differential activity on alpha and beta isoforms
Hanson, Julien ULg; Dogne, J. M.; Ghiotto, J. et al

Poster (2006, November 18)

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of TP receptor antagonists characterized by differential activity on alpha and beta isoforms
Hanson, Julien ULg; Ghiotto, J.; Neven, P. et al

in Acta Pharmacologica Sinica (2006, July), 27

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailCharacterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailSynthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573
Hanson, Julien ULg; Renard, Jean-François ULg; Neven, P. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 12 (2 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, December)

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, November 22)

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailSynthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailEtude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, January 31)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of classical NSAIDS on COX-1 and COX-2 purifies enzymes and prognosis of their effects on physiological responses.
De Leval, X.; Henrotin, Yves ULg; Masereel, B. et al

in Fundamental & Clinical Pharmacology (2003), 14

Detailed reference viewed: 4 (0 ULg)